Source / episode info

• **Episode:**425
• **Title:**Divine Intervention Episode 425: Pulmonary Pathophysiology Series 13
• **Published:**2022-11-08
• Source:Episode page

One-liner

This episode provides an integrated review of {CO}_2 transport mechanisms and acid-base physiology using carbonic anhydrase inhibition, followed by a detailed comparison of obstructive vs. restrictive lung diseases, focusing on the pathophysiology of COPD (chronic bronchitis vs. emphysema) and gas exchange defects.

High-yield summary

• {CO}_2 Transport: The majority of {CO}_2 is transported in red blood cells ( 95\%) via the reaction catalyzed by Carbonic Anhydrase ({CO}_2 + {H}_2{O} -> {H}_2{CO}_3 -> {H}^+ + {HCO}_3^-). The resulting {HCO}_3^- is buffered by the Chloride Shift ({Cl}^- enters RBC as {HCO}_3^- leaves).
• Carbonic Anhydrase Inhibitors (e.g., Acetazolamide): These drugs inhibit CA in the kidney, preventing proximal bicarbonate reabsorption, leading to a loss of {HCO}_3^-, and thus causing a Type 2 RTA. They are also used to treat conditions like Idiopathic Intracranial Hypertension by reducing CSF production.
• Obstructive vs. Restrictive Pattern: Obstructive disease causes air trapping (high lung volumes: {RV}, {FRC}), resulting in a decreased {FEV}_1/{FVC} ratio. Restrictive disease causes reduced compliance and low lung volumes ( {TLC}).
• COPD Pathophysiology: Chronic bronchitis is primarily an airway problem (mucus gland hypertrophy/obstruction). Emphysema is primarily an alveolar problem (parenchymal destruction -> decreased surface area -> reduced {DLCO}).
• Gas Exchange Defects: In chronic bronchitis, hypoxemia results from increased shunt physiology. In emphysema, hypoxemia results from a significantly reduced alveolar surface area ( {DLCO}), and supplemental oxygen may not fully correct the hypoxia.

Learning objectives

• Differentiate between the mechanisms of \text{CO}_2 transport, including the role of carbonic anhydrase and the chloride shift.
• Analyze acid-base disturbances resulting from CA inhibitors (e.g., acetazolamide) and classify them as Type 2 RTA.
• Compare and contrast the physiological findings (PFTs, DLCO, lung volumes) between obstructive and restrictive lung diseases.
• Distinguish the primary pathophysiology of chronic bronchitis (airway inflammation/mucus plugging) from emphysema (alveolar wall destruction).
• Apply knowledge of gas exchange curves (Bohr vs. Haldane effects) to explain changes in oxygen and \text{CO}_2 loading/unloading at different physiological sites.

Board exam buzzwords